Vertaling van "preventing relapses " (Nederlands → Frans) :

TERMINOLOGIE

febris recurrens [Relapsing Fever]
Fièvres récurrentes [borrélioses]

IN-CONTEXT TRANSLATIONS

The approval of Gilenya gives patients a new and convenient treatment option that has shown significant efficacy in reducing symptoms and preventing relapses.
Avec l’homologation de Gilenya, les malades disposent d’une nouvelle option commode qui a démontré son efficacité pour réduire les symptômes et prévenir les rechutes.

(1) De volgende referentie publicatie van W. Kissling is bevestigd door recenter onderzoek: W. Kissling, Duration of Neuroleptic Maintenance Treatment, in W. Kissling Guidelines for Neuroleptic Relapse Prevention, Springer-Verlag Berlin Heidelberg, 1991, pp95-107 (2) Zelfde referentie als 1.
(1) La publication de référence suivante de W. Kissling est confirmée par une étude plus récente : W. Kissling, Duration of Neuroleptic Maintenance Treatment, in W. Kissling Guidelines for Neuroleptic Relapse Prevention, Springer Verlag Berlin Heidelberg, 1991, pp 95-107 (2) Même référence que pour 1.

10. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ et al. Sustainedrelease bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.
10. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ et al. Sustainedrelease Bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.